Schedule 13D ownership disclosure
CASI PHARMACEUTICALS INC
Ordinary Shares · CUSIP: G1933S101
Event date: 2026-03-23
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- WEI-WU HE, Ph.D.Reported CIK 0001542073
Shares: 18,985,535.00 · Class: 53.0%
- HUIYING MEMORIAL FOUNDATION
Shares: 637,644.00 · Class: 3.1%
- EMERGING TECHNOLOGY PARTNERS, LLC
Shares: 16,097,341.00 · Class: 45.3%
- ETP Global Fund L.P.
Shares: 753,234.00 · Class: 3.7%
- ETP BIOHEALTH III FUND, L.P.
Shares: 300,000.00 · Class: 1.5%
- HE Family GRAT
Shares: 100,000.00 · Class: 0.5%
- ETP Global III Fund L.P.
Shares: 15,000,000.00 · Class: 42.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-26-032956
- Form type
- SCHEDULE 13D/A
- Filer
- CASI Pharmaceuticals, Inc.
- CIK
- CIK 1962738
- Filed
- Mar 23, 2026
- Reporting period
- Mar 23, 2026
- Description
- Schedule 13D beneficial ownership